The disclosure relates to methods and compositions for the production of fructans using sucrose:sucrose 1-fructosyl-transferase (1-SST), fructan:fructan 1-fructosyltransferase (1-FFT), and/or sucrose fructan-6-fructosyltransferase (6-SFT) enzymes.

The invention relates to a water-soluble fermented pea extract. The invention also relates to a process for the preparation thereof and to the use thereof in the human and animal nutrition industry as well as in the pharmaceutical, nutraceutical and cosmetics industries.

The present disclosure provides solutions to various challenges in health, including health challenges related to high consumption of carbohydrate and/or low consumption of soluble fiber. The present disclosure provides, among other things, bacteria engineered for expression of a fiber-synthesizing enzyme, e.g., for expression of the enzyme in the gut (e.g., in the intestine). In particular embodiments, the present disclosure provides bacteria engineered for expression of a fiber-synthesizing enzyme that consumes carbohydrate in the process of synthesizing fiber, e.g., in the gut. The present disclosure further includes formulations of isolated fiber-synthesizing enzymes for administration to subjects.

The present invention relates to methods of producing a sugar reduced product from biomass comprising treating the biomass with fermentation enzymes. In an embodiment, treating with fermentation enzymes comprises fermentation. The present invention also relates to sugar reduced products produced by such methods and methods of producing fermentation enzymes.

The instant disclosure provides a genetically modified bacterial cell, i.e., modified Agrobacterium strain, which expresses a levansucrase and has reduced expression of endogenous CysK. As a result, the growth of the modified bacterial cell on medium or tissue culture with sucrose and deficient in cysteine is inhibited. The two-action growth control of the modified Agrobacterium strain can overcome the unmet issue of Agrobacterium overgrowth during plant transformation, and therefore increase the efficiency of plant transformation.

The present invention relates to a recombinant microorganism for producing 2,3-butanediol, in which, in a microorganism having the 2,3-butanediol biosynthetic pathway, at least one selected from a group consisting of a pathway for converting glutamic acid into polyglutamic acid, a pathway for converting sucrose into levan, a pathway for converting pyruvate into lactate, and a pathway for converting glycerophosphate into glycerol is inhibited. The present invention also relates to a method for producing 2,3-butanediol by using the recombinant microorganism for producing 2,3-butanediol.

The invention provides an oligosaccharide debranching enzyme mutant and use thereof in a glucose mother liquor. The mutant is obtained by mutating valine at position 219 in SEQ ID NO: 1 into alanine. According to oligosaccharide debranching enzyme mutant V219A, a primary mother liquor, a secondary mother liquor, or a tail liquid after chromatographic separation is used as a substrate, the percentage contents of glucose in the products are 99.21% (primary mother liquor), 98.89% (secondary mother liquor) and 97.97% (tail liquid after chromatographic separation) respectively, which are 2.86%, 8.64%, and 28.67% higher than that of glucose obtained with the wild-type oligosaccharide debranching enzyme. Therefore, the mutant V219A obviously improves the percentage content of glucose in the glucose mother liquor, and the scope of application of the mother liquor can be expanded by the high product purity and substrate conversion rate, so the mutant V219A has higher industrial application value.

Disclosed are Paenibacillus strains comprising a reduced activity of a flippase PepR aflippase PepH, a mannose-1-phosphate guanylyl transferase and/or a levansucrase SacB. These Paenibacillus strains show lower viscosity when grown in liquid culture and agricultural compositions comprising these strains and methods of making and using these strains.

The invention provides an oligosaccharide debranching enzyme mutant and use thereof in a glucose mother liquor. The mutant is obtained by mutating valine at position 219 in SEQ ID NO: 1 into alanine. According to oligosaccharide debranching enzyme mutant V219A, a primary mother liquor, a secondary mother liquor, or a tail liquid after chromatographic separation is used as a substrate, the percentage contents of glucose in the products are 99.21% (primary mother liquor), 98.89% (secondary mother liquor) and 97.97% (tail liquid after chromatographic separation) respectively, which are 2.86%, 8.64%, and 28.67% higher than that of glucose obtained with the wild-type oligosaccharide debranching enzyme. Therefore, the mutant V219A obviously improves the percentage content of glucose in the glucose mother liquor, and the scope of application of the mother liquor can be expanded by the high product purity and substrate conversion rate, so the mutant V219A has higher industrial application value.

Disclosed are a method for screening a riboswitch capable of specifically recognizing doxycycline as well as rational engineering and application of the riboswitch, and belongs to the field of gene expression regulation. The present disclosure provides a doxycycline specific riboswitch, and establishes a high-throughput screening method based on flow cytometry, and obtains the doxycycline riboswitch with further improved activation fold by way of computer-aided prediction of binding sites of the riboswitch and calculation of mutation sites. According to a dose-response curve, the riboswitch shows linear correlation at 40-100 g/L, and meanwhile, a whole-cell sensor constructed is low in price, high in stability and simple to operate, and can be used for on-site rapid detection.